After a year of exploring the needs in gastrointestinal and colorectal care, Eoin Bambury and Moshe Zilversmit founded Signum Surgical in 2016 as a spin-out of the National University of Ireland BioInnovate programme. Signum Surgical is focused on developing innovative and effective solutions to treat colorectal diseases, starting with anal fistula – a painful and chronic colorectal condition that affects one in 5,000 people worldwide. Requiring only an outpatient procedure, the company’s investigational BioHealx Technology is a minimally invasive, single-hand device developed to provide physicians ease of use, while substantially reducing surgeon training and procedure time, surgical trauma, and recovery time. Signum Surgical most recently secured €4.2 million through two European grant funding awards from the European Union Horizon 2020 SME Instrument and Ireland’s Disruptive Technologies Innovation Fund (DTIF).